Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: A phase I/II study

Clinical Lung Cancer

Volumn 6, Issue 5, 2005, Pages 293-298

  Gatineau, Michel ^a   Rixe, Olivier ^b   Le Chevalier, Thierry ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Muscle cramps; Neutropenia; Ototoxicity; Platinum compounds; Tinnitus

Indexed keywords

CISPLATIN; NAVELBINE; TIRAPAZAMINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEARING IMPAIRMENT; HUMAN; LEUKOPENIA; LOUDNESS RECRUITMENT; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TINNITUS; WEIGHT REDUCTION;

EID: 20744436515     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.008     Document Type: Article

References (32)

1. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311:899-909.
2. Berthaud P, Le Chevalier T, Ruffie P, et al. Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1992; 11:1863-1865.
3. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360-367.
4. Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994; 5:37-42.
5. Wozniak AJ, Crowley JJ, Balcerzak S, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16:2459-2465.
6. Kelly K, Crowley J, Bunn PA, et al. A randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in untreated advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) trial. J Clin Oncol 2001; 19:3210-3218.
7. Gralla, R, Harper P, Johnson S, et al. Vinorelbine (Navelbine) in the treatment of non-small-cell lung cancer: studies with single-agent therapy and in combination with cisplatin. Ann Onco1 1999; 10(suppl 5):S41-S45.
8. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13:139-168.
9. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285-289.
10. Bush RS, Jenkin RD, Allt WE, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 1978; 37:302-306.
11. Gray LH, Conger AD, Ebert M, et al. Concentration of oxygen dissolved in tissues at the time of irradiation as factor in radiotherapy. Br J Radiol 1953; 26:638-648.
12. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88-91.
13. Brown JM. The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999; 59:5863-5870.
14. Teicher BA, Holden SA, al-Achi A, et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990; 50:3339-3344.
15. Tannock I, Guttman P. Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer 1981; 43:245-248.
16. Grau C, Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 1988; 13:301-309.
17. von Pawel J, von Roemeling R, Gatzemer U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small cell lung cancer. A Report of the International CATAPULT I Study Group. J Clin Onco1 2000; 18:1351-1359.
18. Mueller-Klieser W, Vaupel P, Manz R. Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int J Radiat Oncol Biol Phys 1981; 7:1397-404.
19. Brown JM., Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408-1416.
20. Zeman E, Brown MJM, Lemmon MJ et al. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986; 12:1239-1242.
21. Senan S, Rampling R, Graham MA, et al. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 1997; 3:31-38.
22. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993; 53:4633-4636.
23. Johnson C, Kilpatrick AD, von Roemeling R, et al. Phase I trial of tirapazamine in combination with cisplatin in a single dose every three weeks in patients with solid tumors. J Clin Oncol 1997; 15:773-780.
24. Miller VA, Ng KK, Grant SC, et al. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 1997; 8:1269-1271.
25. Treat J, Johnson E, Langer C, et al. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a Phase II study. J Clin Oncol 1998; 16:3524-3527.
26. Aghajanian C, Brown C, O'Flaherty C, et al. Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol Oncol 1997; 67:127-130.
27. Bedikian AY, Legha SS, Eton O, et al. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anticancer Drugs 1999; 10:735-739.
28. Shepherd F, Koschel G, von Pawel J, et al. Comparison of tirazone (tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): final results of the international phase III CATAPULT II trial. Lung Cancer 2000; 29(suppl 1):28.
29. Dorie MJ, Brown JM. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic agent tirapazamine. Cancer Chemother Pharmacol 1997; 39:361-366.
30. Senan, S. Vasoactivity, a potentially important variable in the sequencing of tirapazamine (SR 4233) and radiation [letter; comment]. Int J Radiat Oncol Biol Phys 1995; 31:209-210.
31. Williamson SK, Crowley JJ, Lara PN, et al. S0003: Paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III Southwest Oncology Group (SWOG) Trial. Proc Am Soc Clin Oncol 2003; 22:622 (Abstract #2502).
32. Le QT, McCoy J, Williamson S, et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res 2004; 10:5418-5424.